← Back to Search

Other

SP-624 for Depression

Phase 2
Waitlist Available
Research Sponsored by Sirtsei Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects must meet criteria for moderate to severe Major Depressive Disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
In generally good physical health
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 weeks
Awards & highlights

Study Summary

This study is evaluating whether SP-624 may be an effective treatment for depression.

Eligible Conditions
  • Depression

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Participants must be experiencing symptoms of Major Depressive Disorder that are causing them significant distress or impairment in social, occupational, or other important areas of functioning
Select...
The person is willing and able to comply with the study design schedule and other requirements.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) total score
Secondary outcome measures
Change from Baseline to Week 2 and Week 4 in the 17-item Hamilton Depression Rating Scale (HAM D-17) total score
Change from Baseline to Week 2 and Week 4 in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Change from Baseline to Week 2 and Week 4 in the Quick Inventory of Depressive Symptomology - Self Report (QIDS-SR)
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SP-624Experimental Treatment1 Intervention
Daily oral capsule, 20 mg/day
Group II: PlaceboPlacebo Group1 Intervention
Daily oral capsule
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SP-624
2020
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Sirtsei Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
483 Total Patients Enrolled
1 Trials studying Depression
456 Patients Enrolled for Depression
Greg Rigdon, PhDStudy DirectorSirtsei Pharmaceuticals, Inc.
1 Previous Clinical Trials
456 Total Patients Enrolled
1 Trials studying Depression
456 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
18 - 65
What site did they apply to?
CBH Health
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Email
~68 spots leftby Mar 2025